Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142653852> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2142653852 endingPage "10" @default.
- W2142653852 startingPage "506" @default.
- W2142653852 abstract "Target symptoms in pharmacotherapy of borderline personality disorder include mood instability, anxiety, and impulsivity. Valproate appears useful for the treatment of these target symptoms in several disorders, and carbamazepine has been found effective for such symptoms in borderline personality disorder. We therefore conducted a preliminary open-label trial of valproate in borderline personality disorder.Eleven patients who met DSM-III-R criteria for borderline personality disorder were entered into an 8-week study of valproate. Exclusion criteria included current major depression or major medical disorder. All patients were in psychotherapy at least once a week for a minimum of 8 weeks prior to starting medication. Valproate was increased as tolerated to reach blood levels of 50 to 100 micrograms/mL. Clinician- and self-rated scales were completed each week.Three patients did not complete the study. Of completers, 4 of 8 patients were responders (much less or less) on clinician-rated change scores for overall pathology and for mood. Three of 8 patients were responders on change scores for anxiety, anger, impulsivity, and rejection sensitivity. There was a significant (p = .03) decrease in total Symptom Checklist-90 scores between the start and end of the trial. On the Overt Aggression Scale (Modified), total other-directed assault did not significantly decrease, but there was a significant (p = .02) decrease in global subjective irritability.Valproate led to overall improvement in 50% of a small sample of borderline personality disorder patients who completed an 8-week open trial. The medication was modestly helpful for mood and irritability as well as for anxiety, anger, rejection sensitivity, and impulsivity, but specific therapeutic effects varied from patient to patient. More extensive controlled trials of anticonvulsants for impulsive personality disorders are warranted." @default.
- W2142653852 created "2016-06-24" @default.
- W2142653852 creator A5012058151 @default.
- W2142653852 creator A5027277121 @default.
- W2142653852 creator A5058459271 @default.
- W2142653852 creator A5060810052 @default.
- W2142653852 creator A5085124093 @default.
- W2142653852 date "1995-11-01" @default.
- W2142653852 modified "2023-10-03" @default.
- W2142653852 title "An open trial of valproate in borderline personality disorder." @default.
- W2142653852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7592502" @default.
- W2142653852 hasPublicationYear "1995" @default.
- W2142653852 type Work @default.
- W2142653852 sameAs 2142653852 @default.
- W2142653852 citedByCount "31" @default.
- W2142653852 countsByYear W21426538522015 @default.
- W2142653852 countsByYear W21426538522017 @default.
- W2142653852 countsByYear W21426538522018 @default.
- W2142653852 countsByYear W21426538522020 @default.
- W2142653852 countsByYear W21426538522021 @default.
- W2142653852 crossrefType "journal-article" @default.
- W2142653852 hasAuthorship W2142653852A5012058151 @default.
- W2142653852 hasAuthorship W2142653852A5027277121 @default.
- W2142653852 hasAuthorship W2142653852A5058459271 @default.
- W2142653852 hasAuthorship W2142653852A5060810052 @default.
- W2142653852 hasAuthorship W2142653852A5085124093 @default.
- W2142653852 hasConcept C118552586 @default.
- W2142653852 hasConcept C15744967 @default.
- W2142653852 hasConcept C187288502 @default.
- W2142653852 hasConcept C2777308609 @default.
- W2142653852 hasConcept C2780319597 @default.
- W2142653852 hasConcept C2780600973 @default.
- W2142653852 hasConcept C2780733359 @default.
- W2142653852 hasConcept C2780820931 @default.
- W2142653852 hasConcept C558461103 @default.
- W2142653852 hasConcept C70410870 @default.
- W2142653852 hasConcept C77805123 @default.
- W2142653852 hasConceptScore W2142653852C118552586 @default.
- W2142653852 hasConceptScore W2142653852C15744967 @default.
- W2142653852 hasConceptScore W2142653852C187288502 @default.
- W2142653852 hasConceptScore W2142653852C2777308609 @default.
- W2142653852 hasConceptScore W2142653852C2780319597 @default.
- W2142653852 hasConceptScore W2142653852C2780600973 @default.
- W2142653852 hasConceptScore W2142653852C2780733359 @default.
- W2142653852 hasConceptScore W2142653852C2780820931 @default.
- W2142653852 hasConceptScore W2142653852C558461103 @default.
- W2142653852 hasConceptScore W2142653852C70410870 @default.
- W2142653852 hasConceptScore W2142653852C77805123 @default.
- W2142653852 hasIssue "11" @default.
- W2142653852 hasLocation W21426538521 @default.
- W2142653852 hasOpenAccess W2142653852 @default.
- W2142653852 hasPrimaryLocation W21426538521 @default.
- W2142653852 hasRelatedWork W1964626496 @default.
- W2142653852 hasRelatedWork W1990747296 @default.
- W2142653852 hasRelatedWork W2010478642 @default.
- W2142653852 hasRelatedWork W2037990712 @default.
- W2142653852 hasRelatedWork W2039207569 @default.
- W2142653852 hasRelatedWork W2537965945 @default.
- W2142653852 hasRelatedWork W2765401905 @default.
- W2142653852 hasRelatedWork W3000356174 @default.
- W2142653852 hasRelatedWork W3216339924 @default.
- W2142653852 hasRelatedWork W4225649464 @default.
- W2142653852 hasVolume "56" @default.
- W2142653852 isParatext "false" @default.
- W2142653852 isRetracted "false" @default.
- W2142653852 magId "2142653852" @default.
- W2142653852 workType "article" @default.